Open‐label investigation of rapid initiation of extended‐release buprenorphine in patients using fentanyl and fentanyl analogs
The American Journal on Addictions · 2024
DOI: 10.1111/ajad.13484 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal on Addictions, 2024. Verfasst von John J Mariani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division on Substance Use Disorders, New York State Psychiatric Institute, New York, New York, USA. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Indivior UK Limited.
Abstract (Originalsprache)
Background and Objectives Synthetic opioids, including fentanyl and fentanyl analogs, account for over 70,000 annual overdose deaths in the United States, but there is limited information examining methods of induction and maintenance outcomes for buprenorphine treatment of patients with opioid use disorder (OUD) using these opioids.
Methods
A secondary analysis of results grouped by fentanyl use status was completed for an open‐label study with rapid induction of extended‐release buprenorphine in the inpatient research unit. Eligible participants received a single 4 mg dose of transmucosal buprenorphine (BUP‐TM) followed by an extended‐release buprenorphine 300 mg injection ([BUP‐XR]) after approximately 1 h. An extension study continued follow‐up up to 6 months (6 monthly injections).
Results
Among participants with fentanyl‐positive urine samples (FEN+; n = 19), all received BUP‐TM, 17 received BUP‐XR, 13 elected to receive a second BUP‐XR injection, and 10 received all six scheduled injections. Among participants with fentanyl‐negative samples (FEN−; n = 7), all received BUP‐TM and BUP‐XR, four elected to receive a second injection, and two participants received all six scheduled injections. Induction day clinical opioid withdrawal scale (COWS) scores were similar for FEN+ and FEN− groups. In the FEN+ group, mean COWS scores fell to below 5 within 24 h of BUP‐XR injection. Discussion and Conclusions The treatment of individuals with OUD using fentanyl with a rapid 1‐day induction to BUP‐XR 300 mg injection is feasible and well‐tolerated. Scientific Significance A prospective trial of participants grouped by fentanyl use status at induction demonstrates comparable patient retention and clinical response following single‐day induction of BUP‐XR in participants who are FEN+ and FEN−.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division on Substance Use Disorders, New York State Psychiatric Institute, New York, New York, USA.
- Department of Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.
- Global Medicines Development, Indivior Inc., Richmond, Virginia, USA.
- Hassman Research Institute, CenExel, Berlin, New Jersey, USA.
ORCID-Profile: John J Mariani
Förderung
- Indivior UK Limited
Zitieren
APA
Mariani, J. J., Dobbins, R. L., Heath, A., Gray, F., & Hassman, H. (2024). Open‐label investigation of rapid initiation of extended‐release buprenorphine in patients using fentanyl and fentanyl analogs. The American Journal on Addictions. https://doi.org/10.1111/ajad.13484
Vancouver
Mariani JJ, Dobbins RL, Heath A, Gray F, Hassman H. Open‐label investigation of rapid initiation of extended‐release buprenorphine in patients using fentanyl and fentanyl analogs. The American Journal on Addictions. 2024. doi:10.1111/ajad.13484
BibTeX
@article{Mariani2024,
author = {Mariani, John J and Dobbins, Robert L and Heath, Amy and Gray, Frank and Hassman, Howard},
title = {Open‐label investigation of rapid initiation of extended‐release buprenorphine in patients using fentanyl and fentanyl analogs},
journal = {The American Journal on Addictions},
year = {2024},
doi = {10.1111/ajad.13484}
}
EUVIMED